A core myth about Contract Research Organizations (CROs) is that they are primarily bioscience companies. The more effective operational view is that they are in the data business. Their main function is to deliver high-quality, actionable, and auditable data, which shifts the strategic focus to process, technology, and data standardization.

Despite processing 15 million clinical charts, Datycs doesn't use this data for model training. Their agreements explicitly respect that data belongs to the patient and the client—an ethical choice that prevents them from building large, aggregated language models from customer data.

While ensuring patient access through co-pay cards and prior authorizations was once the primary focus, it has now become table stakes. Leading pharmaceutical companies are shifting investment toward perfecting the 'day one' experience, recognizing that a poor initial self-administration can lead to immediate therapy abandonment.

Instead of a fragmented 'kitchen sink' approach, pharmaceutical companies should first deeply understand patient pain points. This understanding then guides the selection and coordination of various specialized vendors, ensuring a seamless and effective support system that avoids overwhelming the patient.

A common failure in biotech is viewing patients solely as data sources rather than as human partners in the development process. This perspective leads to unnecessarily complex protocols with high patient burden. The most successful firms build relationships with patient advocacy groups and design trials that respect the patient's experience.

As AI tools increasingly guide patient diagnosis and treatment recommendations, pharma's focus must shift. The primary challenge is no longer just influencing the HCP directly, but ensuring your product data is structured to "win" in the AI's algorithmic suggestions.

Despite generating enormous amounts of data from hubs, specialty pharmacies, and copay programs, the data remains siloed. This fragmentation prevents a holistic patient view, leading to poor decision-making, patient non-adherence, and significant avoidable healthcare costs.

The current model burdens hospitals with perpetual data storage liability. Enigma Genetics proposes offloading data ownership to individuals, who then grant access. Hospitals and pharma would pay for access as needed, transforming a costly institutional liability into a controlled, patient-centric transaction.

The competitive advantage in pharma isn't the sophistication of an AI algorithm, which is often a commodity built on third-party models. The true differentiator is the quality, relevance, and end-to-end consistency of the proprietary data used to train and validate these models. Poor data invalidates even the best analytics.